Pathologic Treatment Effect and Survival in HPV-Negative HNSCC Following Neoadjuvant Nivolumab
About this episode
This episode features an interview with the authors discussing the impact of neoadjuvant nivolumab on survival in HPV-negative head and neck squamous cell carcinoma.
Interview with Jennifer M. Johnson, MD, PhD and Adam J. Luginbuhl, MD authors of A Pathologic Treatment Effect and Survival in HPV-Negative HNSCC Following Neoadjuvant Nivolumab. Hosted by Paul C. Bryson, MD MBA. Related Content: Pathologic Treatment Effect and Survival in HPV-Negative HNSCC Following Neoadjuvant Nivolumab Emerging Role of Pathologic Response in Head and Neck Squamous Cell Carcinoma Immunotherapy
More episodes of JAMA Otolaryngology–Head & Neck Surgery Author Interviews
- Federal Funding in Otolaryngology–Head and Neck Surgery
- Amivantamab for Recurrent or Metastatic Adenoid Cystic Carcinoma
- Why Hearing Health Must Be Part of Voice Biomarker Research
- Biofeedback vs Respiratory Retraining for Inducible Laryngeal Obstruction
- Evaluation of Practice Patterns for 6-Sinus Balloon Sinus Dilation
- The JAMA Otolaryngology-Head & Neck Surgery Editorial Fellowship Experience
Explore listener stats, chart rankings, contacts and more on the JAMA Otolaryngology–Head & Neck Surgery Author Interviews podcast page.